Phase 3 clinical trial focuses on adults with moderate-to-severe chronic hand eczema
News
Spago Nanomedical begins endometriosis study
Clinical trial has received regulatory approval and involves endometriosis candidate SN132D
FDA grants fast-track designation for Istesso’s IPF candidate
The therapy has reduced inflammation and supported the remodelling of damaged bone
Valneva shares positive chikungunya vaccine results
99% of participants retained very high neutralising antibody levels 12 months after treatment
Merck KGaA’s arpraziquantel validated by European Medicines Agency
Positive scientific opinion by EMA would create pathway for arpraziquantel in African endemic countries
Healthcare leaders warn about unsustainable pressure on mental health services
Patients and service users routinely struggle to access mental healthcare across the NHS
Valneva and Pfizer report Lyme disease antibody data
Children and adults have been treated using the Lyme disease antibody candidate VLA15
Respiratory vaccination candidate tested in German hospitals
Novel tuberculosis vaccine tested in a large phase 3 trial against severe respiratory infection disease
Eisai and Biogen present promising lecanemab study results
Phase 3 research shows that Alzheimer’s disease treatment meets primary and secondary endpoints
Otsuka receives vital Lupkynis MHRA authorisation
Therapy represents first oral calcineurin-inhibitor treatment for active lupus nephritis in adults
Touchlight receives funding to develeop DNA vaccine platform
Bill & Melinda Gates Foundation grant will boost potential of nanoparticle-formulated doggybone DNA
Immutep in clinical trail collaboration with Merck KGaA and Pfizer
Research will focus on eftilagimod alpha and avelumab for the treatment of urothelial cancer
Almirall joins project to allow study participants to use trial data
Project involves 27 partners including patient associations, hospitals and universities
C4XD signs NRF2 Activator deal with AstraZeneca
C4XD will receive milestone payments worth up to $16m ahead of the first clinical trial
Bristol Myers Squibb immunotherapy-chemo combination gets NICE recommendation
Treatment involves adults with certain forms of advanced stomach and oesophageal cancer
